• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Alliance Global Partners initiated coverage on Sorrento Therapeutics

    1/21/21 10:28:55 AM ET
    $SRNE
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SRNE alert in real time by email
    Alliance Global Partners initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $35
    Get the next $SRNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRNE

    DatePrice TargetRatingAnalyst
    11/2/2022$5.00Overweight
    Cantor Fitzgerald
    8/9/2021$30.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SRNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

      PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

      7/5/22 2:04:42 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji

      SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento's Chairman and CEO Henry Ji. Governor Thompson's appointment is effective immediately. Most recently, Thompson served as the President of the University of Wisconsin System from July 2020 through March 2022, one of the largest

      6/24/22 3:38:28 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

      SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche Laboratories executive, Tammy Reilly, to Sorrento's board of directors. Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer merchandising and healthcare diagnostic companies to Sorrento.  "Sorrento continues to strengthen its already experienced board of directors," said Henry Ji, Ph.D., Chairman and Chief Executive O

      5/18/22 9:00:00 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SRNE
    Financials

    Live finance-specific insights

    See more
    • Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

      US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

      1/31/25 9:00:00 AM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Posts Form 8937 to Supplement its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")

      SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company ("Scilex") previously held by Sorrento. The Form 8937 has been filed with the Internal Revenue Service and Sorrento expects to send copies of the form in the coming days to brokerage firms, banks, dealers and similar organizations to whom a dividend confirmation had previously been distr

      2/18/23 8:37:04 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Issues Update to its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")

      SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an update to its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento (the "Dividend Stock"). The update to the FAQs provides notice regarding the no lien code added on Scilex (NASDAQ:SCLX) common stock that was distributed as a dividend to Sorrento's stockholders and provides notice to brokerage firms, banks, dealers and similar organizations listed therein that a

      2/17/23 3:47:31 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    $SRNE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

      US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

      1/31/25 9:00:00 AM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 Case

      SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento's $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento's chapter 11 case, which was filed on February 13, 2023.  The financing will provide Sorrento with immediate liquidity so that it can continue operating its business as usual during its chapter 11 case. A hearing for final approval of

      2/21/23 5:57:00 PM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Sorrento Posts Form 8937 to Supplement its Previously Issued "FAQ" Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, "Scilex")

      SAN DIEGO, Feb. 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))) today posted an IRS Form 8937 (the "Form 8937") to supplement its previously issued "Frequently Asked Questions" document under the "Investors" section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company ("Scilex") previously held by Sorrento. The Form 8937 has been filed with the Internal Revenue Service and Sorrento expects to send copies of the form in the coming days to brokerage firms, banks, dealers and similar organizations to whom a dividend confirmation had previously been distr

      2/18/23 8:37:04 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SRNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sorrento Therapeutics Inc. (Amendment)

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      3/10/23 11:21:36 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Sorrento Therapeutics Inc.

      SC 13G - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/17/23 4:07:18 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G/A filed by Sorrento Therapeutics Inc. (Amendment)

      SC 13G/A - Sorrento Therapeutics, Inc. (0000850261) (Subject)

      2/9/23 3:48:42 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SRNE
    SEC Filings

    See more
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      11/7/23 4:34:31 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      11/3/23 5:31:06 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Sorrento Therapeutics, Inc. (0000850261) (Filer)

      10/5/23 5:26:12 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SRNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Sorrento Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Sorrento Therapeutics with a rating of Overweight and set a new price target of $5.00

      11/2/22 6:29:52 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sorrento Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00 from $30.00 previously

      8/9/21 6:25:18 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • B. Riley Securities initiated coverage on Sorrento Therapeutics with a new price target

      B. Riley Securities initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $26.00

      1/29/21 7:40:31 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $SRNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sorrento Therapeutics Inc.

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      3/20/23 7:52:53 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 5: Janda Kim closing all direct ownership in the company

      5 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      2/6/23 9:10:05 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: Ji Henry exercised 500 in-the-money shares at a strike of $5.50

      4 - Sorrento Therapeutics, Inc. (0000850261) (Issuer)

      12/23/22 2:28:10 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care